Wire · operational-macro
Biohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
The FDA placed a partial clinical hold on Biohaven's BHV-7000 epilepsy trials due to insufficient preclinical data on a metabolite's safety in humans. This regulatory action halted new patient enrollment pending further nonclinical studies, reflecting the FDA's strict enforcement of metabolite safety guidelines.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 10 Sep 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You must secure complete metabolite safety data before pivotal trials start or risk costly clinical holds. Biohaven’s pause shows regulatory bodies will enforce this strictly, so tighten preclinical readiness now.
◆ Coverage
4 sources · first reported 10 Sep 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics